Trials / NCT01530659
Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
Completed Phase 2 Cell therapy
- Sponsor
- Neurotech Pharmaceuticals
- Treatment
- NT-501; Sham
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Usher Syndrome Type 3
- Ages
- 18 Years to 55 Years
- Enrollment
- 22 participants
- Started
- 2012-01
- Main results expected
- 2019-07-01
- Results posted
- Yes
- Record last updated
- 2023-02-14
What the study is testing
This clinical trial is a single-site, 30 patient study for participants who have early stage retinitis pigmentosa, or Usher syndrome (type 2 or 3). Funding Source - FDA OOPD and Foundation Fighting Blindness.
Where it runs
United States (1)
- University of California, San Francisco, San Francisco, California